Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib with Chemoradiation in Gynecological Cancers
NCT03345784Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in Cervical Cancer (CC), vaginal cancer and uterine cancer, sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose. Started May 2018; status: terminated.
02
Drugs
adavosertib
03
Conditions
Cervical Cancer (CC)vaginal canceruterine cancer
Beyond the preview
Go deeper on NCT03345784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345784.